June 16 (Reuters) - Antisense Therapeutics Ltd ANP.AX
* Phase II study has shown atl1102 significantly reduces number of active MS lesions that convert to "black holes" Source text for Eikon: Further company coverage: ANP.AX
June 16 (Reuters) - Antisense Therapeutics Ltd ANP.AX
* Phase II study has shown atl1102 significantly reduces number of active MS lesions that convert to "black holes" Source text for Eikon: Further company coverage: ANP.AX